Browse a selection of key resources and publications about our pipeline.

2025 WCLC REZILIENT1

Zipalertinib in Patients With Epidermal Growth Factor Receptor Exon 20 Insertion-Positive Non–Small Cell Lung Cancer Previously Treated With Platinum-Based Chemotherapy With or Without Amivantamab (2025 JCO)

Efficacy of Zipalertinib in NSCLC Patients With EGFR Exon 20 Insertion Mutations Who Received Prior Platinum-Based Chemotherapy With or Without Amivantamab (2025 ASCO)

A Phase 1, Open-Label, Dose-Escalation and Dose-Expansion Study of CLN-049 for the Treatment of Acute Myeloid Leukemia Patients With Measurable Residual Disease (2024 ASH)

CLN-978: Mechanism of Action: T Cell Engagers

Mechanism of Action: T Cell Engagers

Modulating the Immune System: An Intricate Balancing Act

Advances in Autoimmune Diseases: A Conversation with Dr. Ricardo Grieshaber-Bouyer

CLN-978, A CD19-Directed T-Cell Engager (TCE), Leads to Rapid and Deep B-Cell Depletion and Has Broad Potential for Development in Autoimmune Diseases (2024 ACR)

Safety and Antitumor Activity of Zipalertinib in NSCLC Patients With EGFR Exon 20 Insertion Mutations Who Received Prior Amivantamab (2024 ESMO)